Following the strategy established through IS-panel-10, the combination of STING-LNP and the CTLA4 antibody in the 4T1 tumor model resulted in significant tumor suppression, despite the cancer being resistant to immunotherapy, including immune checkpoint inhibitors. This evidence concerns the gene STING1 and cancer.